Date:10/15/2008

mprove patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

'/>"/>

SOURCE Masimo Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
2. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
3. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
4. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
5. Masimo Reports First Quarter 2008 Financial Results
6. Atom Medical Adopts Masimo Rainbow SET Technology
7. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
8. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
9. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
10. Masimo Announces Continuous Noninvasive Total Hemoglobin
11. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group